WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017186711) NOVEL COMPLEXES OF IMMUNOSTIMULATORY COMPOUNDS, AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/186711    International Application No.:    PCT/EP2017/059781
Publication Date: 02.11.2017 International Filing Date: 25.04.2017
IPC:
A61K 31/7084 (2006.01), A61K 31/7076 (2006.01), A61K 31/708 (2006.01), A61K 33/42 (2006.01), A61K 9/00 (2006.01), A61P 35/00 (2006.01), A61P 31/00 (2006.01)
Applicants: INVIVOGEN [FR/FR]; ZI de Montaudran 5, rue Jean Rodier 31400 TOULOUSE (FR)
Inventors: VERNEJOUL, Fabienne; (FR).
BOULARAN, Cédric; (FR).
DROCOURT, Daniel; (FR).
LIOUX, Thierry; (FR).
QUSHAIR, Grégory; (FR).
ROMO, Jésus; (US).
TIRABY, Gérard; (FR)
Agent: CABINET PLASSERAUD; 66 rue de la Chaussée d'Antin 75440 PARIS CEDEX 09 (FR)
Priority Data:
16305481.0 25.04.2016 EP
Title (EN) NOVEL COMPLEXES OF IMMUNOSTIMULATORY COMPOUNDS, AND USES THEREOF
(FR) NOUVEAUX COMPLEXES DE COMPOSÉS IMMUNOSTIMULATEURS, ET LEURS UTILISATIONS
Abstract: front page image
(EN)The present invention concerns the preparation of complexes formed between a cationic lipid and at least one of various cyclic dinucleotide (CDN) agonists of STING, and proposes uses of such complexes. Specifically, such complexes can be used to provide enhanced or distinct biological activities in vitro, ex vivo or in vivo, relative to use of the corresponding CDN component alone.
(FR)La présente invention concerne la préparation de complexes formés entre un lipide cationique et au moins un des divers agonistes dinucléotidiques cycliques (CDN) de STING, et des utilisations desdits complexes. Plus spécifiquement, ces complexes peuvent être utilisés pour obtenir des activités biologiques améliorées ou distinctes in vitro, ex vivo ou in vivo, par rapport à l'utilisation du composant CDN correspondant seul.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)